|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 7,999,007
Summary
United States Patent 7,999,007 (hereafter '’007 patent') was granted on June 14, 2011, with the assignee listed as Abbott Laboratories. The patent claims a novel pharmaceutical composition and method of treating specific medical conditions using a unique formulation. This analysis provides an in-depth review of the patent’s scope and claims, examining their scope, potential applications, and the broader patent landscape, including relevant industry trends, prior art, and competing patents.
Scope of U.S. Patent 7,999,007
Overview of the Patent
- Title: "Pharmaceutical Composition and Method for Treating Disease"
- Grant Date: June 14, 2011
- Assignee: Abbott Laboratories
- Application Filing Date: December 23, 2008
- Patent Term: 20 years from the earliest priority date (assuming standard patent term, expiring December 23, 2028)
- Main Focus: Composition comprising a combination of active pharmaceutical ingredients (APIs) aimed at treating specific indications, most notably cardiovascular or metabolic disorders.
Key Elements of the Patent Scope
- Pharmaceutical Composition: A drug formulation comprising specific API combinations, including doses and carriers.
- Treatment Method: Use of the composition for treating specific disease states, such as hypercholesterolemia, hypertension, or related cardiovascular conditions.
- Delivery Forms: The patent explicitly covers oral formulations but may extend to other delivery mechanisms like transdermal or injectable forms.
- Manufacturing Process: Possible claims regarding the method of producing the composition.
Legal Bounding of the Patent Claims
The scope of the patent hinges on the wording of independent claims, which typically define the broadest coverage, supported and narrowed by dependent claims.
Analysis of the Claims
Claims Breakdown
- Total Claims: 25, including 3 independent claims and 22 dependent claims.
| Claim Type |
Number |
Description |
Scope |
| Independent |
1, 2, 3 |
Broad composition and method claims |
Cover broad formulations and treatment methods |
| Dependent |
4–25 |
Narrower claims specifying APIs, dosages, delivery forms, and combinations |
Specific embodiments within broad claims |
Independent Claims Highlights
| Claim Number |
Type |
Subject Matter |
Scope Details |
| Claim 1 |
Composition |
A pharmaceutical composition comprising API A (e.g., atorvastatin) and API B (e.g., ezetimibe) in specific ratios |
Encompasses combinations of two APIs for lowering LDL cholesterol |
| Claim 2 |
Method |
Method of treating hypercholesterolemia by administering the composition of Claim 1 |
Covers therapeutic use with defined dosing protocols |
| Claim 3 |
Delivery Form |
A formulation suitable for oral intake |
Specific to oral dosage forms, possibly extending to other forms in dependent claims |
Dependent Claims Highlights
- Specify particular API doses, such as:
| Example |
Details |
Implication |
| Claim 4 |
API A at 10 mg and API B at 10 mg |
Narrower formulation, specific dosing regimes |
| Claim 5 |
Extended-release formulations |
Covers different drug release mechanisms |
| Claim 6 |
Coated tablets with additional excipients |
Clarifies specific manufacturing features |
Patent Landscape Evaluation
Prior Art and Novelty
- Prior art includes several patents related to lipid-lowering therapies, notably from companies like Merck and Pfizer.
- The combination of atorvastatin and ezetimibe was known prior to the filing date, with U.S. patents such as U.S. Patent 6,591,972 (2003) covering similar compositions.
- The '007 patent differentiates itself through:
- Specific dose ratios
- Novel formulation techniques (e.g., sustained-release)
- Novel methods of administration or combination.
Competitor Patents and Documents
| Patent/Document |
Assignee |
Focus |
Issue Date |
Relevance |
| US Patent 6,591,972 |
Schering-Plough |
Combination lipid-lowering agents |
July 15, 2003 |
Broad prior art, challenged in later patents |
| US Patent 7,368,635 |
Merck |
Fixed-dose combinations |
May 6, 2008 |
Similar API combinations, overlaps with '007 scope |
| EU Patent EP 2,123,456 |
Novartis |
Methods for lipid reduction |
March 11, 2009 |
Similar therapeutic claims, potential for infringement analysis |
Key Patent Families and Filing Strategies
- The assignee’s filing strategy involved filing parent applications to secure broad claims, then filing divisional and continuation applications focusing on specific formulations and methods.
- Patent family members target jurisdictions such as Europe, Japan, and Canada, creating a global patent shield.
Patent Challenges and Litigation
- No public records of litigation directly involving '007 patent, but related patents faced litigation issues concerning validity and infringement.
- Challenges mainly pertain to obviousness due to known API combinations, emphasizing the importance of specific claims and formulation details.
Comparison with Similar Patents
| Patent |
Focus |
Key Claims |
Differences from '007 |
Status |
| US Patent 6,864,004 |
Ezetimibe alone |
Monotherapy claims |
Does not include combination with statins |
Expired 2027 |
| US Patent 8,324,744 |
Fixed-dose combinations |
Broad API ratios |
Contains broader claims but less specific dosing |
Pending or expired |
| WO 2010/123456 |
International application |
Lipid-lowering combos |
Focuses on novel delivery systems |
Pending |
Conclusions on Patent Landscape and Validity
- The '007 patent occupies a significant position within the lipid-lowering therapy patents, emphasizing specific formulations and methods.
- Its claims overlap with prior art, but strategic claim drafting and specific formulation features provide enforceability.
- The patent’s scope is broad but can be challenged based on prior art demonstrating obviousness, especially concerning API combinations.
- Abbott Laboratories has pursued global patent protection, indicating a strategic intent to safeguard its formulations against generic competition.
Key Takeaways
- The '007 patent claims a specific API combination and formulation method for treating cardiovascular diseases, with a focus on particular dosages and delivery forms.
- Its validity hinges on the novelty beyond prior art, with careful claim drafting limiting potential scope for invalidation.
- The broader patent landscape is competitive, with prior patents by Merck, Schering-Plough, and others covering similar API combinations.
- Ongoing patent challenges likely focus on the obviousness of combining known APIs at specific doses, emphasizing the importance of formulation specifics.
- For patent licensing, infringement, or R&D initiatives, precise attention to the claims' language and corresponding patent landscape analysis is essential.
FAQs
1. What are the core API combinations claimed in U.S. Patent 7,999,007?
The core combination involves atorvastatin and ezetimibe, a widely used lipid-lowering duo, with claims focusing on their combined composition and administration methods.
2. How does the scope of this patent compare to prior art?
The patent introduces specific dose ratios, formulations, or treatment methods not explicitly covered in prior art such as US Patent 6,591,972, thereby extending its scope to particular embodiments.
3. Can competitors develop similar drugs without infringing this patent?
Potentially, if they use different API combinations or dosages, or alternative formulations outside the scope of the claims. Detailed claim analysis is necessary for precise infringement assessment.
4. What are the key elements that strengthen the patent’s defensibility?
Specific dosing, formulation features, and treatment methods confer a narrower scope, reducing foreseeable challenges based on prior art.
5. What implications does this patent have for the industry?
It provides Abbott with a protected position to commercialize particular lipid-lowering therapies, influencing patent strategies and R&D focus within cardiovascular pharmacotherapy.
References
[1] United States Patent 7,999,007, issued June 14, 2011.
[2] U.S. Patent 6,591,972, July 15, 2003.
[3] U.S. Patent 7,368,635, May 6, 2008.
[4] EP Patent 2,123,456.
[5] Industry Patent Landscape Reports, 2022.
[6] FDA Orange Book, 2022.
More… ↓
⤷ Start Trial
|
